Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Soars On Supinoxin Tidal Wave


Dallas, Texas 03/18/2014 (FINANCIALSTRENDS) –  Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) may have found its muse in its RX-5902, now named Supinoxin finally. With the first-stage results of Supinoxin announced last week, the clinical-stage therapy appears to meet requirements for treating nervous system disorders as well as cancer. More importantly, Supinoxin is found to hit the right chemicals to break down solid cancer tumors.

Telling Results

Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN) has announced that the results, which are of the Phase One Study, begun in the eight month of last year is yet to achieve MTD or Maximum Tolerated Dose and is ongoing.

Currently, the cycles were completed thrice and there has been no trace of anti-drug issues.

Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN) in its press release noted that, “Pharmacokinetic analysis has shown that SupinoxinTM displays dose-proportional exposure and an estimated oral bioavailability of 51%.”

Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN), in the context of the results thus far has proved to be drug which does trigger immediate anti-factors. Instead patients have indicated higher tolerance. The current results are aligned with the preliminary clinical studies as well.

Full Phase Data to define RNN future

However, Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN) awaits the full results of the Phase One study, which are likely to be available by the end of the year, when the study of this phase will end.

Cautious outlook

Though, current investors in RNN do hope the results of these initial studies and first-stage human trials relate to the final results, experts in this sector, do advice caution.

First, the drug is yet to achieve a critical MTD value. Once this is recognized the real-time viability of Supinoxin comes into picture. Besides, efficacy factors too need to be established, before Supinoxin becomes popular for treating solid tumors as well as disorders of the nervous system.

RNN currently holds a market capital of $59.80 million and trades at infra-day prices between $1.28 and $1.29 per share.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.